📊 ATRA Key Takeaways
Is Atara Biotherapeutics, Inc. (ATRA) a Good Investment?
Atara Biotherapeutics exhibits severe financial distress with negative stockholders' equity of -$38.5M despite profitable income statement metrics, indicating balance sheet insolvency. The company burns $50.9M in operating cash flow annually while generating only $120.8M in revenue, creating an unsustainable cash burn rate that threatens operational continuity without external financing.
Despite reported operating and net profitability, the company’s earnings quality appears weak because cash generation is deeply negative, with operating cash flow and free cash flow both at -$50.94M. The balance sheet is highly stressed, with only $8.48M of cash, a sub-1.0 current ratio, and negative stockholders’ equity, which materially raises financing and going-concern risk unless fundamentals improve quickly.
Why Buy Atara Biotherapeutics, Inc. Stock? ATRA Key Strengths
- High operating margin of 29.7% and net margin of 27.1% demonstrate operational profitability on reported earnings
- Positive net income of $32.7M and operating income of $35.9M show business can generate earnings
- Interest coverage ratio of 9.5x indicates ability to service debt obligations from operations
- Reported operating margin of 29.7% and net margin of 27.1% indicate headline profitability in the latest period
- Revenue base of $120.77M provides some operating scale relative to the company’s asset base
- Interest coverage of 9.5x suggests current earnings are presently sufficient to cover interest expense
ATRA Stock Risks: Atara Biotherapeutics, Inc. Investment Risks
- Negative stockholders' equity of -$38.5M signals balance sheet insolvency and technical bankruptcy status
- Operating cash flow of -$50.9M vastly exceeds net income, indicating earnings quality issues and cash burn fundamentally unsustainable
- Current ratio of 0.82x and quick ratio of 0.82x show insufficient liquid assets to cover short-term liabilities; immediate liquidity crisis risk
- Total liabilities of $58.7M exceed total assets of $20.2M by nearly 3x, representing structural financial distress
- FCF margin of -42.2% demonstrates business model cannot sustain operations without external capital raises
- Operating cash flow and free cash flow are strongly negative, indicating poor earnings quality and cash burn
- Negative stockholders’ equity and total liabilities far above total assets point to severe balance-sheet weakness
- Current and quick ratios of 0.82x imply constrained near-term liquidity and potential need for external capital
Key Metrics to Watch
- Operating cash flow trend and path to cash flow breakeven
- Stockholders' equity recovery and balance sheet recapitalization
- Cash burn rate and months of liquidity remaining
- Revenue growth sustainability and operating leverage improvement
- Operating cash flow/free cash flow trend versus reported net income
- Cash balance and current ratio, including any changes in liabilities or equity restoration
Atara Biotherapeutics, Inc. (ATRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ATRA Profit Margin, ROE & Profitability Analysis
ATRA vs Healthcare Sector: How Atara Biotherapeutics, Inc. Compares
How Atara Biotherapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Atara Biotherapeutics, Inc. Stock Overvalued? ATRA Valuation Analysis 2026
Based on fundamental analysis, Atara Biotherapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Atara Biotherapeutics, Inc. Balance Sheet: ATRA Debt, Cash & Liquidity
ATRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Atara Biotherapeutics, Inc.'s revenue has grown significantly by 103% over the 5-year period, indicating strong business expansion. The most recent EPS of $-11.41 indicates the company is currently unprofitable.
ATRA Revenue Growth, EPS Growth & YoY Performance
ATRA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $2.1M | -$19.0M | $-2.93 |
| Q2 2024 | $957.0K | -$19.0M | $-3.10 |
| Q1 2024 | $1.2M | -$31.8M | $-0.23 |
| Q3 2023 | $2.1M | $18.5M | $-0.66 |
| Q2 2023 | $957.0K | $18.5M | $0.18 |
| Q1 2023 | $1.2M | -$74.8M | $-0.72 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Atara Biotherapeutics, Inc. Dividends, Buybacks & Capital Allocation
ATRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Atara Biotherapeutics, Inc. (CIK: 0001604464)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ATRA
What is the AI rating for ATRA?
Atara Biotherapeutics, Inc. (ATRA) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ATRA's key strengths?
Claude: High operating margin of 29.7% and net margin of 27.1% demonstrate operational profitability on reported earnings. Positive net income of $32.7M and operating income of $35.9M show business can generate earnings. ChatGPT: Reported operating margin of 29.7% and net margin of 27.1% indicate headline profitability in the latest period. Revenue base of $120.77M provides some operating scale relative to the company’s asset base.
What are the risks of investing in ATRA?
Claude: Negative stockholders' equity of -$38.5M signals balance sheet insolvency and technical bankruptcy status. Operating cash flow of -$50.9M vastly exceeds net income, indicating earnings quality issues and cash burn fundamentally unsustainable. ChatGPT: Operating cash flow and free cash flow are strongly negative, indicating poor earnings quality and cash burn. Negative stockholders’ equity and total liabilities far above total assets point to severe balance-sheet weakness.
What is ATRA's revenue and growth?
Atara Biotherapeutics, Inc. reported revenue of $120.8M.
Does ATRA pay dividends?
Atara Biotherapeutics, Inc. does not currently pay dividends.
Where can I find ATRA SEC filings?
Official SEC filings for Atara Biotherapeutics, Inc. (CIK: 0001604464) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ATRA's EPS?
Atara Biotherapeutics, Inc. has a diluted EPS of $2.57.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ATRA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Atara Biotherapeutics, Inc. has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ATRA stock overvalued or undervalued?
Valuation metrics for ATRA: ROE of N/A (sector avg: 15%), net margin of 27.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ATRA stock in 2026?
Our dual AI analysis gives Atara Biotherapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ATRA's free cash flow?
Atara Biotherapeutics, Inc.'s operating cash flow is $-50.9M, with capital expenditures of $0.0. FCF margin is -42.2%.
How does ATRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 27.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.82 (avg: 2).